HIKMA PHARMACEUTICALS ORD GBP0.10HH

HIKMA PHARMACEUTICALS ORD GBP0.10

2,090GBXD
−6−0.29%
At close at 15:47 GMT
GBX
No trades
See on Supercharts

HIK fundamentals

Key facts

Market capitalization‪4.62 B‬GBP
Founded1978
Employees (FY)‪9.5 K‬
CEORiad Mishlawi
Websitehikma.com
About

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.

Ownership
‪‪220.43 M‬‬
Free Float shares
‪‪154.44 M‬‬ (70.06%)
Closely held shares
‪‪65.99 M‬‬ (29.94%)
Free Float shares
‪‪154.44 M‬‬ (70.06%)
Closely held shares
‪‪65.99 M‬‬ (29.94%)
Capital structure
Market cap
‪‪4.62 B‬‬
Debt
‪‪1.04 B‬‬
Minority interest
‪‪8.78 M‬‬
Cash & equivalents
‪‪170.07 M‬‬
Enterprise value
‪‪5.50 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪4.62 B‬‬
Price to earning ratio (P/E)
16.63x
Price to sales ratio (P/S)
1.91x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
16.63x
Price to sales ratio (P/S)
1.91x
Valuation ratios
‪0.00‬
‪0.50‬
‪1.00‬
‪1.50‬
‪2.00‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪9.00‬
‪18.00‬
‪27.00‬
‪36.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪1.0%‬
‪4.5%‬
‪8.0%‬
‪11.5%‬
‪15.0%‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪‪350.00 M‬‬
‪‪700.00 M‬‬
‪‪1.05 B‬‬
‪‪1.40 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪350.00 M‬‬
‪‪700.00 M‬‬
‪‪1.05 B‬‬
‪‪1.40 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪350.00 M‬‬
‪‪700.00 M‬‬
‪‪1.05 B‬‬
‪‪1.40 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Injectables
Generics
Branded
Other
By country
Period: 2024
United States
Middle East and North Africa
Saudi Arabia
Europe and Rest of the World
Algeria
North America
United Kingdom

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪0.00‬
‪‪350.00 M‬‬
‪‪700.00 M‬‬
‪‪1.05 B‬‬
‪‪1.40 B‬‬
Actual
Estimate
Earnings
Next:Aug 7, 2025
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪0.00‬
‪0.26‬
‪0.52‬
‪0.78‬
‪1.04‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
48.63%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
2.95%
Last payment
0.37
Last ex-date
Mar 20, 2025
Last pay date
May 1, 2025
Dividend history
‪1.0%‬
‪1.6%‬
‪2.2%‬
‪2.8%‬
‪3.4%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.16‬
‪0.32‬
‪0.48‬
‪0.64‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪‪300.00 M‬‬
‪‪600.00 M‬‬
‪‪900.00 M‬‬
‪‪1.20 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪600.00 M‬‬
‪‪1.20 B‬‬
‪‪1.80 B‬‬
‪‪2.40 B‬‬
Assets
Liabilities